

- **Name:** **Yoon-Koo KANG**
 - **Current Position & Affiliation:** **Professor, ASAN Medical Center**
 - **Country:** **Korea**
-

• **Educational Background:**

1975. 3 – 1977. 2 Pre-Medicine
College of Natural Sciences
Seoul National University, Seoul, Korea

1977. 3 – 1981. 2 M.D.
College of Medicine
Seoul National University, Seoul, Korea

1987. 3 – 1989. 2 Master of Science
Postgraduate School
Seoul National University, Seoul, Korea

1989. 3 – 1992. 2 Ph.D.
Postgraduate School
Seoul National University, Seoul, Korea

• **Professional Experience:**

1989. 3 – 1999. 10 Chief
Section of Hematology/Oncology
Department of Internal Medicine
Korea Cancer Center Hospital, Seoul, Korea

1992. 3 – 1993. 5 Research Fellow in Medicine Branch
National Cancer Institute
NIH of U.S.A.

1995. 1 – 1999. 10 Chief
Laboratory of Experimental Therapeutics
Korea Cancer Center Hospital, Seoul, Korea

1999. 12 – 2002. 2 Associate Professor
Division of Oncology/Hematology
Department of Internal Medicine
Asan Medical Center

University of Ulsan College of Medicine, Seoul, Korea

2002. 3 - Present Professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine, Seoul, Korea

2003. 1 – 2008. 2 Chief
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine, Seoul, Korea

2006. 1 – 2007. 8 Director
Clinical Research Center
Asan Medical Center, Seoul, Korea

• **Professional Organizations:**

Chairman of IRB, Korean Cancer Study Group 2010 - 2012
Chairman, Korean GIST Study Group since Jan 2007 - Dec 2017
Chairman, World Congress of GI Cancer: Asian Perspectives 2007 - 2012
President, Korea Cancer Study Group Mar 2012 – Feb 2016
President, Korean Society of Medical Oncology (KSMO) June 2017- May 2018
Chair, GI tumors, non-colorectal Track, Scientific Steering Committee of ESMO
2018

• **Main Scientific Publications:**

Published over 395 peer-reviewed manuscripts, 174 papers as corresponding author and 28 papers as first author. —Key publications for GIST are listed below.

Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. *Oncologist*. 2020 Jun 26. [Epub ahead of print]

Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. *Oncologist*. 2019 Dec;24(12):e1443-e1449

Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. *Cancer Med*. 2019 Mar;8(3):1034-1043